ビットカジノ 入金方法 Work-style
Along with adhering to all laws, regulations, and codes of conduct in both letter and spirit, and promoting compliance with high ethical standards, the Kyorin Group is engaged in activities that appropriately manage internal anビット カジノ 入金 不要xternal business-related risks with the aim of continuously enhancing corporate value.
Each Group company has a Compliance Committee and a Risk Management Committee, which work to propose various policies and raise awareness, promote compliance and risk management, and prevent legal and regulatory violations.
Compliance
Basic Policy
An enterprise is required to promote the realization of a sustainable society through ビット カジノ 入金 不要reation of added value and employment that are useful to society and through autonomous and responsible actions based on fair and free competition.
Following our corporate philosophy, the Kyorin Group conducts its activities in Japan and overseas based on a high standard of corporate ethics, in compliance with both the letter and the spirit of relevant laws, regulations, and international rules.
Corporate Charter ビット カジノ 入金 不要ompliance Guidelines
Using ビット カジノ 入金 不要orporate Ethics and Compliance Guidelines, in August 2006, we formulated ビット カジノ 入金 不要orporate Charter and ビット カジノ 入金 不要ompliance Guidelines, which were revised in April 2019 to reflect our commitment to a sustainable society and again in April 2023 to reflect the Group’s restructuring and changes including legal revisions and social developments.
- The KYORIN Pharmaceutical Corporate Charter was developed to specify matters of corporate ethics ビット カジノ 入金 不要ompliance in accordance with our corporate philosophy, and serves as the starting point for our corporate activities.
- ビット カジノ 入金 不要ompliance Guidelines complement the KYORIN Pharmaceutical Corporate Charter by clarifying the standards to be followed for sound and proper business activities.
- ビット カジノ 入金 不要ompliance Committee was established to provide overall supervision of corporate ethics and compliance systems. Each Kyorin company has a compliance promotion manager who is responsible for the understanding and instilling of corporate ethics and compliance.
We are also building a structure to promote compliance, including the establishment of a Compliance Committee, which is chaired by ビット カジノ 入金 不要orporate officer responsible for compliance and led by Legal and Corporate Compliance. ビット カジノ 入金 不要ommittee meets monthly and reports regularly on ビット カジノ 入金 不要ontent of its meetings to the Management Committee.
Respect for human rights
Kyorin’s respect for human rights is outlined in ビット カジノ 入金 不要orporate Charter and ビット カジノ 入金 不要ompliance Guidelines. The Group is managed with an understanding of international norms related to human rights and with a priority on respect for the human rights of all people.
We have also established guidelines to prevent harassment including sexual harassment, harassment related to pregnancy, childbirth, childcare leave and nursing care leave, as well as for the prevention of “power harassment” by managers toward their subordinates.
Education and Training
Internal training is held to ensure an understanding of and familiarity with Kyorin’s corporate philosophy ビット カジノ 入金 不要ompliance.
- Companywide level-specific training (newly hireビット カジノ 入金 不要mployees, newly appointed managers, etc.) and functional training are held to teach corporate ethics and compliance, anビット カジノ 入金 不要fforts are made to ensure that an understanding and consideration of compliance are reflected in the work performed by directors, corporate auditors and officers, anビット カジノ 入金 不要mployees.
- We have designated June and November as twice-yearly “compliance enforcement months” and are working to ensure that compliance is thoroughly understood and practiced through initiatives designated for each department anビット カジノ 入金 不要mployee.
Internal whistleblowing system
The Kyorin Group has established a “Corporate Ethics Hotline” to accept inquiries, consultations, and reports regarding corporate ethics and responses to laws and regulations, etc. The Group also accepts whistleblower reports of suspected injustice or non-compliance via internal and external points of contact. We strictly maintain ビット カジノ 入金 不要onfidentiality of whistleblowers, respect their privacy, and ensure that they are not disadvantaged.
Whistleblowing reports: reports: 5 in fiscal 2023
Risk Management
The Kyorin Group companies have established the Risk Management Committee, which is held once a month to develop a management system that seeks to prevent the occurrence of risks and handle any risks that arise.
The details of these meetings are regularly reported to the Management Committee. The Risk Management Committee oversees risk management initiatives across the entire Group, while also promoting activities to be implemented as necessary at respective divisions to build a structure to identify potential risks, reduce risks, and prevent risk events from occurring, and to minimize the damage from risk events that do occur unavoidably. If a problem arises, it will be reported to ビット カジノ 入金 不要orporate officer in charge in a timely manner. In the event of a natural disaster or other risk that could significantly impact business, a Contingency Measures Headquarters, headed by the president, will be established to manage ビット カジノ 入金 不要risis.
Initiatives Related to Transparency in Relationships with Medical Institutions and Other Parties
The mission of a pharmaceutical company is to contribute to the health and welfare of people around the world through ongoing research and the development of high-value new drugs that address medical needs and by providing stable supplies of those drugs. To fulfill this mission, partnerships with pharmaceutical companies, research laboratories, and medical institutions including universities and others are essential, and we are required to properly manage our relationships where there is a potential conflict of interest with pharmaceutical companies.
Against this backdrop, the Kyorin Group has established the Guidelines for Transparency of Relationships between Corporate Activities and Medical Institutions, etc., and the Guidelines on Collaboration with Patient Groups and Transparency of Their Activities. In accordance with these guidelines, we disclose information about funding to medical institutions, patient groups, and others on our website.